Resmed (RMD) Common Equity (2010 - 2026)

Resmed has reported Common Equity for 17 years, with the latest figure at $6.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 17.05% year-over-year to $6.5 billion; the trailing twelve-month figure through Mar 2026 stood at $6.5 billion (up 17.05% YoY), and the FY2025 full-year result was $6.0 billion, up 22.69% from the prior year.
• Common Equity for Q1 2026 stood at $6.5 billion, up from $6.3 billion in the prior quarter.
• The five-year high for Common Equity was $6.5 billion in Q1 2026, with the low at $3.3 billion in Q1 2022.
• Historically, Common Equity has averaged $4.8 billion across 5 years, with a median of $4.6 billion in 2024.
• Annual changes were most pronounced in 2022 — Common Equity rose 13.44% — and 2023, when it increased 23.81%.
• Resmed's Common Equity stood at $3.7 billion in 2022, then rose by 19.9% to $4.5 billion in 2023, then rose by 17.21% to $5.3 billion in 2024, then gained by 20.33% to $6.3 billion in 2025, then grew by 2.71% to $6.5 billion in 2026.
• The last three Common Equity figures came in at $6.5 billion (Q1 2026), $6.3 billion (Q4 2025), and $6.1 billion (Q3 2025), per Business Quant data.